Furthermore, Batf3-deficient (Batf3−/−) mice implanted with FGL2KO tumor cells lacked both CD103+ DCs and CD8a+ DCs in their brains and TDLNs compared with WT C57BL/6 mice (Fig. 4a), suggesting that FGL2KO tumor cell-mediated CD103+ DCs development depends on Batf3, which is known as a crucial regulator of CD103+/CD8a+ DCs in other tumor model systems18–20. This evidence concerns the gene CD8A and neoplasm.